OncoMatch/Clinical Trials/NCT06166576
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
Is NCT06166576 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres. This trial specifically targets patients diagnosed with hepatocellular carcinoma accompanied by localized portal vein tumor thrombosis (Vp1-Vp3) and who maintain good liver function.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Leukocytes ≥ 2,500/µL and ≤ 12,000/µL; Absolute neutrophil count ≥ 1,500/mm^3; Hemoglobin ≥ 8.0 g/dL (transfusions allowed); Platelets ≥ 50,000/µL; For patients not on anticoagulants, INR ≤ 2.0
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
Total bilirubin ≤ 3.0 mg/dL; AST ≤ 200 IU/L (≤ 5X ULN); ALT ≤ 200 IU/L (≤ 5X ULN); ALP ≤ 575 IU/L (≤ 5X ULN); Child-Pugh class A
Patients without serious dysfunction of major organs, as indicated by blood tests conducted within one month of study enrollment 1. Leukocytes ≥ 2,500/µL and ≤ 12,000/µL 2. Absolute neutrophil count ≥ 1,500/mm^3 3. Hemoglobin ≥ 8.0 g/dL (transfusions allowed to meet this criterion) 4. Total bilirubin ≤ 3.0 mg/dL 5. Platelets ≥ 50,000/µL 6. For patients not on anticoagulants, INR ≤ 2.0 7. AST ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 8. ALT ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 9. ALP ≤ 575 IU/L (i.e., ≤ 5X upper normal limit) 10. Creatinine ≤ 2.0 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify